Patients with liver cancer will develop liver function indicators as the severity of the disease gradually worsens, mainly manifesting as reduced or impaired liver function. Elevated transaminases and decreased protein levels, especially albumin, are found during liver function tests, which are mainly related to the greatly reduced ability to synthesize albumin after liver function is impaired. Markers of liver malignancy, such as alpha-fetoprotein, may also be abnormally elevated. The normal value is 0-20 μg/L, but when liver cancer occurs, the value of AFP alpha-fetoprotein may be greater than 500 μg/L or more. As the disease evolves, changes in liver and kidney function may occur, including abnormally high creatinine and urea nitrogen, and patients may have elevated blood ammonia, which may lead to hepatic encephalopathy and even coma under certain triggers.